v3.25.3
Investments Accounted for Using the Equity Method - Summary of Investments in Associates and Joint Ventures (Details) - EUR (€)
€ / shares in Units, € in Millions
2 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2025
Jun. 30, 2024
[1],[2]
Dec. 31, 2024
Disclosure of transactions between related parties [line items]        
Investments accounted for using the equity method [1] € 3,563 € 3,563   € 316
Share of profit/(loss) from investments accounted for using the equity method 11 € 85 [1] € (22)  
EUROAPI        
Disclosure of transactions between related parties [line items]        
Proportion of ownership interest in associate [3]   29.60%    
Investments in associates [3] 82 € 82   82
Opella        
Disclosure of transactions between related parties [line items]        
Proportion of ownership interest in associate [4]   48.20%    
Investments in associates [4] € 3,239 € 3,239   € 0
Loans to Associates   € 241    
OPAL JV Co [Member]        
Disclosure of transactions between related parties [line items]        
Proportion of ownership interest in associate   48.20%    
CD&R [Member]        
Disclosure of transactions between related parties [line items]        
Proportion of ownership interest in associate   50.00%    
Bpifrance [Member]        
Disclosure of transactions between related parties [line items]        
Proportion of ownership interest in associate   1.80%    
EUROAPI        
Disclosure of transactions between related parties [line items]        
Stock price (in euro per share) € 2.89 € 2.89   € 2.88
MSP Vaccine Company | MCM Vaccine BV        
Disclosure of transactions between related parties [line items]        
Proportion of ownership interest in subsidiary   100.00%    
Infraserv GmbH & Co. Höchst KG        
Disclosure of transactions between related parties [line items]        
Proportion of ownership interest in joint venture [5]   31.20%    
Investments in joint ventures [5] € 93 € 93   € 102
MSP Vaccine Company        
Disclosure of transactions between related parties [line items]        
Proportion of ownership interest in joint venture [6]   50.00%    
Investments in joint ventures [6] 79 € 79   81
Other investments        
Disclosure of transactions between related parties [line items]        
Proportion of ownership interest in joint venture   0.00%    
Investments in joint ventures € 70 € 70   € 51
[1] These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi’s audited consolidated financial statements as of December 31, 2024.
[2] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[3] The investment in EUROAPI includes an impairment loss booked in prior years determined by reference to the quoted market price (€2.89 as of June 30, 2025, and €2.88 as of December 31, 2024).
[4] Following the loss of control of Opella, Sanofi holds 48.2% of OPAL JV Co (CD&R holds 50% and Bpifrance holds 1.8%), see Note B.1.. As of June 30, 2025, the investment includes a €241 million loan to OPAL JV Co being in substance part of the investment.
[5] Joint venture.
[6] Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV.